Cole, Christian;Reigan, Philip;Gbaj, Abdul;Edwards, Philip N.;Douglas, Kenneth T.;Stratford, Ian J.;Freeman, Sally;Jaffar, Mohammed published 《Potential Tumor-Selective Nitroimidazolylmethyluracil Prodrug Derivatives: Inhibitors of the Angiogenic Enzyme Thymidine Phosphorylase》 in 2003. The article was appeared in 《Journal of Medicinal Chemistry》. They have made some progress in their research.Application of 18592-13-7 The article mentions the following:
Thymidine phosphorylase (TP) is an angiogenic growth factor and a target for anticancer drug design. Mol. modeling suggested that 2′-aminoimidazolylmethyluracils would be potent inhibitors of TP. The novel 5-halo-2-aminoimidazolylmethyluracils were very potent inhibitors of E. coli TP (IC50 ∼ 20 nM). Contrastingly, the corresponding 2′-nitroimidazolylmethyluracil (as bioreductively activated) prodrugs were 1000-fold less active (IC50 22-24 μM). This approach may be used to selectively deliver TP inhibitors into hypoxic regions of solid tumors where TP is overexpressed. To complete the study, the researchers used 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7) .
6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Application of 18592-13-7) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.
Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia